Research map: Integrating clinically actionable biomarkers into bladder cancer care — recommendations from the International Bladder Cancer Group

Back to the article

Papers in this map

  1. Tumor mutational load predicts survival after immunotherapy across multiple cancer types · Robert M. Samstein · 2019 · 4457 citations · Cited by this paper
  2. Urolithiasis in patients with cancer · 2026 · Related
  3. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic · Timothy An-thy Chan · 2018 · 2934 citations · Cited by this paper
  4. Bladder cancer research is blossoming in Birmingham · 2026 · Related
  5. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative Group on HNPCC☆ · Hans F. A. Vasen · 1999 · 2531 citations · Cited by this paper
  6. Animal models of spinal cord injury in neuro-urological research · 2026 · Related
  7. Bladder Cancer · Andrew Thomas Lenis · 2020 · 1849 citations · Cited by this paper
  8. Transitional urology: a comprehensive review of the transitional care process · 2026 · Related
  9. European Association of Urology Guidelines on Non–muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ) · Marko M. Babjuk · 2021 · 1710 citations · Cited by this paper
  10. Why counting women is not enough: from inclusion to equity in oncology trials · 2026 · Related
  11. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity · Margaret A. Knowles · 2014 · 1293 citations · Cited by this paper
  12. Polypropylene mesh degradation and systemic disease: biological plausibility is not clinical evidence · 2026 · Related
  13. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma · Thomas B. Powles · 2021 · 1236 citations · Cited by this paper
  14. Leveraging generative AI to enhance doctor–patient communication · 2026 · Related
  15. Assessment of a HER2 scoring system for gastric cancer: results from a validation study · Manfred Hofmann · 2008 · 1203 citations · Cited by this paper
  16. Neoadjuvant intraprostatic immunotherapy for high-risk localized prostate cancer · 2026 · Related
  17. Association Between Smoking and Risk of Bladder Cancer Among Men and Women · Neal D. Freedman · 2011 · 1174 citations · Cited by this paper
  18. The role of neoantigens and tumor mutational burden in cancer immunotherapy: advances, mechanisms, and perspectives · 2025 · Related
  19. Liquid biopsy and minimal residual disease — latest advances and implications for cure · Klaus Pantel · 2019 · 1126 citations · Cited by this paper
  20. Molecular Profiling of Urothelial Bladder Cancer: Bridging Tumor Biology and Clinical Decision-making · 2026 · Related
  21. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma · Dean F. Bajorin · 2021 · 1090 citations · Cited by this paper
  22. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  23. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model · Jesús María Fernández Gómez · 2009 · 668 citations · Cited by this paper
  24. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial · Thomas B. Powles · 2021 · 660 citations · Cited by this paper
  25. Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma · Emil Christensen · 2019 · 564 citations · Cited by this paper
  26. Bladder cancer · Lars Dyrskjøt · 2023 · 541 citations · Cited by this paper
  27. European Association of Urology (EAU) Prognostic Factor Risk Groups for Non–muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel · Richard J Sylvester · 2021 · 484 citations · Cited by this paper
  28. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment · Jeffrey M. Holzbeierlein · 2024 · 420 citations · Cited by this paper
  29. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma · Yohann Loriot · 2023 · 337 citations · Cited by this paper
  30. Open-label, Multicenter, Phase II Study of RC48-ADC, a HER2-Targeting Antibody–Drug Conjugate, in Patients with Locally Advanced or Metastatic Urothelial Carcinoma · Xinan Sheng · 2020 · 289 citations · Cited by this paper
  31. Radical cystectomy versus trimodality therapy for muscle-invasive bladder cancer: a multi-institutional propensity score matched and weighted analysis · Alexandre R. Zlotta · 2023 · 268 citations · Cited by this paper
  32. Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma · David Liu · 2016 · 264 citations · Cited by this paper
  33. What Is the Significance of Variant Histology in Urothelial Carcinoma? · Niyati Lobo · 2019 · 252 citations · Cited by this paper
  34. Nonoperative Management of Mismatch Repair–Deficient Tumors · Andrea Cercek · 2025 · 216 citations · Cited by this paper
  35. A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage · Bas W.G. van Rhijn · 2011 · 193 citations · Cited by this paper
  36. A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer · Omar Fahmy · 2017 · 187 citations · Cited by this paper
  37. Efficacy and Safety of Disitamab Vedotin in Patients With Human Epidermal Growth Factor Receptor 2–Positive Locally Advanced or Metastatic Urothelial Carcinoma: A Combined Analysis of Two Phase II Clinical Trials · Xinan Sheng · 2023 · 180 citations · Cited by this paper
  38. Evaluation of urovysion and cytology for bladder cancer detection · Haythem Dimashkieh · 2013 · 173 citations · Cited by this paper
  39. Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome · Fay Kastrinos · 2017 · 170 citations · Cited by this paper

Source: OpenAlex (CC0)